NanoViricides, Inc. (NYSE American: NNVC) announced that the Pillar Committee in Charge in the Democratic Republic of Congo has approved the company's proposal to conduct a Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company stated that NV-387 is a broad-spectrum antiviral designed to target host-cell features required by viruses and is the only orally administered Ebola treatment candidate currently under consideration for clinical testing, to its knowledge.
According to the press release, the next steps include obtaining approvals from the DRC National Ethics Committee and regulatory agency ACOREP before initiating the study. NanoViricides noted that NV-387 Oral Gummies have already received authorization in the DRC for a Phase II mpox trial and are ready for shipment. Management believes the oral formulation could offer significant advantages in resource-limited outbreak settings, where intravenous treatments can be difficult to deploy and scale.
NanoViricides is a clinical stage company that creates special purpose nanomaterials for antiviral therapy. The company's lead drug candidate is NV-387, a broad-spectrum antiviral drug being developed for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections and Measles. The company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus.
The approval from the DRC Pillar Committee marks a significant milestone for NanoViricides as it advances NV-387 into Phase II human clinical trials. The oral formulation of the drug could address critical challenges in deploying treatments during Ebola outbreaks, particularly in regions with limited healthcare infrastructure. The company's technology is based on intellectual property, technology, and proprietary know-how of TheraCour Pharma, Inc., and NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms.
For more information, see the full press release at https://nnw.fm/1ewVT. The latest news and updates relating to NNVC are available in the company's newsroom at https://nnw.fm/NNVC.
